ABOUT US
In an industry where vertical integration keeps the largest PBMs locked into a profit-first mindset we’ve fundamentally rewritten the playbook.
At LucyRx, we’re reimagining pharmacy benefits with independence, transparency, smarter technology, and a commitment to putting people first. Backed by a $500 million capital investment, LucyRx partners with 60,000+ pharmacies and over 4,000 clients nationwide, serving more than 1.65 million members.
The name Lucy, which comes from Latin meaning “light,” perfectly symbolizes our mission: to shine a clear light on the path forward in pharmacy benefit management.
OUR MISSION
We pioneer new and simpler paths to better health for every individual we serve.
By forging partnerships with like-minded community leaders and utilizing the most advanced technologies, we deliver innovative strategies and customer-centric solutions for more effective and affordable pharmacy care. . . because everyone deserves to live a better, healthier life.
Our Values
Integrity
Innovation
Humanity
Leadership That Puts You First
With decades of healthcare experience, our leadership team is tackling the flaws of traditional PBMs head-on — driving down costs, redefining pharmacy care, and delivering real value.
David Blair
Chief Executive Officer
David Blair has over 25 years of experience investing in and operating companies in the pharmacy services and ancillary markets. In 2023, David Blair, along with other leading industry professionals, founded LucyRx in response to the pressing demand for value-added pharmaceutical services companies. Serving as the Chief Executive Officer of LucyRx, David’s team aims to offer vital solutions for health plans grappling with substantial rises in complex, high-cost specialty drugs.
From 1998 through 2012, Mr. Blair served as chairman and chief executive officer of Catalyst Health Solutions Inc., a Fortune 500 company that was acquired by SXC Health Solutions in 2012 for $4.8 billion.
On average, Catalyst doubled in size every two years, earning a position on Fortune’s 100 Fastest-Growing Companies list five times and recognition as a Fortune 500 company in 2012. Catalyst was also the recipient of numerous prestigious healthcare and financial industry awards including Fortune’s “World’s Most Admired Companies”; the Washington Post 200, URAC Award for Best Practices in Health Care; e-Healthcare Leadership Awards; Interactive Media Awards for its drug pricing tools and three Pharmacy Benefit Management Institute Rx Benefit Innovation Awards.
Mr. Blair’s management skills and accomplishments resulted in numerous awards and recognition including Forbes America’s 15 Most Powerful CEOs under 40 (years of age). In addition to his philanthropic activities, Mr. Blair has remained active in the healthcare industry since the sale of Catalyst. Mr. Blair has both started and invested in numerous healthcare companies, including Gateway Health Partners, among others in the healthcare and pharmacy services spaces. Mr. Blair holds a B.A. in finance from Clemson University.
Lankford Wade
President and Chief Financial Officer
Lankford Wade is a transformative leader with more than 20 years of experience driving financial excellence and operational growth in the healthcare sector. As President and Chief Financial Officer of LucyRx, he oversees financial strategy and operations, ensuring the company delivers innovative, cost-effective solutions to clients while maintaining the highest standards of operational efficiency.
Lankford’s career is defined by a commitment to delivering value for stakeholders. Before joining LucyRx, he served as CEO of UpStream, where he repositioned the company for improved financial performance while advancing patient care initiatives. As CFO of Summit Health, Lankford was instrumental in scaling the organization, integrating the Summit Medical Group and CityMD, navigating tremendous growth in the face of the COVID-19 pandemic, and leading the company through its $8.9 billion acquisition by VillageMD.
Beyond his operational achievements, Lankford brings extensive expertise in building scalable infrastructure and fostering growth. At U.S. Anesthesia Partners and Aetna, he spearheaded initiatives to enhance financial systems, optimize operations, and deliver measurable results for clients and stakeholders.
A summa cum laude graduate of Princeton University with a degree in Economics, Lankford’s extensive experience reflects a commitment to innovation, strategic leadership, and delivering impactful results.
Martin Payne
EVP, Chief Strategy Officer
Martin J. Payne, has more than 30 years of experience in executive and board positions in a mix of private and public, global enterprises. Mr.Payne’s current board positions are with SK Growth Opportunities (NASDAQ: SKGRU) and Astraius, a satellite launch company.
Mr. Payne has served in board leadership positions at MedX and Comprehensive Clinical Solutions, where he led strategic and operational transformation efforts, including the successful, over-subscribed, IPO launch of HCARU, raising over $330 million.
In addition to multiple entrepreneurial successes, Mr. Payne was formerly with Catalyst Health Solutions (formerly NASDAQ: CHSI), leading the highly value-accretive M&A transactions and integrations of HospiScript, IPS, Total Script, InPharmative, Future Scripts, Walgreens Health Initiatives, and RegenceRx; during which time Catalyst’s stock price rose fourfold. Prior to his tenure with Catalyst, Mr. Payne served in executive leadership roles at Coventry Health Care (formerly NYSE: CVH), Hanger Orthopedic Group (NYSE: HNGR), and United Health Group (NYSE: UNH).
Mr. Payne started his career in the Royal Navy as a helicopter pilot. Mr. Payne is a graduate of the University of Essex.
Alexander Motola
EVP, Chief Business Officer
Mr. Motola has over a decade of experience in finance, healthcare investing, and capital markets. He has completed 30+ M&A transactions representing over $10 billion in aggregate transaction value. His investment experience spans the capital structure (including majority and minority equity, senior and junior debt) and company stage (public, buyout, growth, and venture).
From 2021 to 2023, Mr. Motola served as a senior investment professional at a boutique special situations private equity fund focused on the healthcare and technology sectors, where he led transaction sourcing and execution, as well as operational value creation initiatives. Prior to that, he held investment and advisory roles at Baird, Twin Brook Capital Partners (a subsidiary strategy of Angelo, Gordon), and BMO Capital Markets. Mr. Motola earned his B.B.A. in Finance and Economics from the University of Iowa and his M.B.A. from UCLA Anderson School of Management.
Susan Thomas
Chief Commercial Officer
Susan Thomas has more than 30 years of experience in healthcare, specialty pharmacy, and pharmacy benefit management, combining a clinical background in nursing with deep commercial and operational leadership. She serves as Chief Commercial Officer at LucyRx, where she is responsible for expanding and growing the company’s commercial business and overseeing all market-facing initiatives. In this role, Ms. Thomas leads sales, clinical strategy, marketing and branding, and client success management, working with employers and consultants to design and deliver prescription benefit solutions that meet the needs of plan sponsors and members.
Before joining LucyRx, Ms. Thomas held senior roles at several national PBMs and health services organizations. She served as Senior Vice President of Growth and Retention and Vice President/General Manager of Client Services at Elixir, Vice President and General Manager for FutureScripts and Vice President for the Health Plan segment at OptumRx, and Vice President of Account Management for the employer segment at Catamaran, formerly SXC and Catalyst Rx. Across these roles, she led large account management and service teams, managed significant revenue portfolios, and was accountable for client growth, retention, and service performance. Earlier in her career, she held leadership positions in specialty pharmacy and home infusion at organizations including CVS ProCare, TheraCom, and Inova Health System, managing oncology and complex patient care services.
Ms. Thomas holds a Bachelor of Science in Nursing and a Master of Business Administration from the University of Virginia, including the Darden School of Business. She is a licensed registered nurse and brings that frontline experience to her work with clients and teams. In 2025, she received Silver and Bronze Stevie® Awards for Women in Business in the categories of Most Innovative Woman of the Year – Healthcare and Female Executive of the Year.
Lori Hart
Chief Human Resources Officer
Lori Hart is an accomplished human resources leader with more than 20 years of experience driving talent strategy, organizational development, and workforce transformation across the healthcare industry. As Chief Human Resources Officer at LucyRx, she leads all aspects of talent strategy, culture, and people operations, ensuring the company attracts, develops, and retains top talent to support its rapid growth and mission to transform pharmacy benefits.
Before joining LucyRx, Lori served as Vice President of Human Resources at Compassus, where she led HR strategy for a workforce of nearly 6,000 employees across hospice, home health, and palliative care services. Prior to that, she was Vice President of Human Resources at Option Care Health, where she played a key role in workforce integration following the company’s merger with BioScrip, helping to scale the business to over $3 billion in revenue.
Lori brings deep expertise in talent development, leadership coaching, mergers and acquisitions, workforce planning, and employee engagement. She has also held HR leadership roles at UnitedHealth Group/OptumRx, Oregon Lottery, and IHS Markit, where she developed scalable HR infrastructures, implemented strategic workforce initiatives, and guided organizations through periods of growth and change.
A Gallup Strengths Performance Coach, Lori is passionate about creating purpose-driven workplaces where employees thrive. She has also served on multiple nonprofit boards, reflecting her commitment to community impact and leadership.
Anuj Agrawal
Chief Transformation Officer
Anuj Agrawal is a strategic technology leader with over 25 years of experience in healthcare and pharmacy benefits management (PBM). As Chief Transformation Officer at LucyRx, he is responsible for driving the company’s digital transformation and operational innovation, leading the migration from on-premise infrastructure to the cloud to enhance scalability, security, and regulatory compliance. Anuj’s leadership ensures that LucyRx’s technology ecosystem remains at the forefront of data security and AI-driven innovation, with a strong commitment to HIPAA and SOC 2 Type 2 alignment.
Before joining LucyRx, Anuj held senior leadership positions at Elixir and UnitedHealth Group (Optum), where he spearheaded technology modernization and transformation initiatives. At Elixir, he served as Head of Technology Services, leading the modernization of PBM platforms, rebate aggregation systems, and core systems integration. At Optum, Anuj oversaw UnitedHealthcare’s flagship portals, mobile platforms, and clinical systems supporting complex specialty care, while also leading major cloud migration initiatives and implementing AI-driven solutions to boost efficiency and cost savings.
Anuj holds a Master of Science in Computer Science from the University of Missouri-Kansas City and a Bachelor of Science in Mechanical Engineering from the National University of Singapore. His career reflects a commitment to leveraging technology for strategic growth and operational excellence, positioning LucyRx as a leader in healthcare innovation and data-driven solutions.
Danielle Drzewucki
Chief Supply Chain Officer, Strategic Services and Solutions
Danielle Drzewucki has more than 20 years of experience in the pharmacy benefit management and healthcare industries, with deep expertise in supply chain, finance, and enterprise strategy. She serves as Chief Supply Chain Officer, Strategic Services and Solutions at LucyRx, where she leads drug sourcing, solution development, and vendor relationships. Ms. Drzewucki and her team are responsible for optimizing manufacturer and pharmacy contracts, reducing net drug costs, and enhancing formulary management so plan sponsors achieve meaningful savings without compromising clinical quality or member access.
Ms. Drzewucki joined LucyRx following senior leadership roles at several national PBMs and health services companies. Most recently, she served as Chief Financial Officer of CitizensRx, where she led the finance organization across budgeting, forecasting, capital allocation, and strategic planning, while partnering with the executive team on growth and acquisition initiatives. Previously, she held multiple leadership positions at Express Scripts and Cigna, including Chief Financial Officer for Specialty and Home Delivery Pharmacy, Vice President of Risk Management and Underwriting, and Vice President of Supply Chain Forecasting and Analytics. In these roles, she managed multibillion-dollar P&Ls, developed competitive pricing and underwriting strategies, supported major transactions, and led teams that improved rebate performance, purchasing efficiency, and overall margin in the pharmacy supply chain.
Throughout her career, Ms. Drzewucki has led teams and initiatives that connect financial performance with better outcomes for clients and members. She holds a Bachelor of Arts in Finance and Accounting from Southern Illinois University at Carbondale and a Master of Business Administration from Webster University.
Christin L. Bassett
Chief Legal Officer, LucyRx
Christin Bassett has more than 25 years of experience advising boards and executive teams in highly regulated healthcare and pharmacy organizations. She serves as Chief Legal Officer at LucyRx, where she leads the company’s legal strategy and provides counsel on risk management, corporate governance, contracting, and the legal and ethical dimensions of how LucyRx serves its clients and members. In this role, Ms. Bassett works closely with the senior leadership team on growth initiatives, including mergers and acquisitions, government programs, and new product development, while overseeing the legal operations that support LucyRx’s work as a prescription care partner.
Prior to joining LucyRx, Ms. Bassett held senior legal and leadership roles at Rite Aid Corporation, where she served as Acting General Counsel and Corporate Secretary and previously as Group Vice President, Deputy General Counsel. In those roles she advised the board and executive leadership on legal and regulatory risk as both a public and private company, led legal, privacy, information governance, and regulatory and government affairs teams, and supported complex asset sales and financing transactions. Earlier, she served as Corporate Counsel at Otsuka America Pharmaceutical, Inc., and as Executive Director and Senior Counsel at Aetna Inc., where she led consumer litigation and class action matters across pharmacy, medical, and behavioral health benefits. She also held in-house roles at AstraZeneca Pharmaceuticals LP and began her career in private practice at national law firms focusing on pharmaceutical, medical device, and commercial litigation.
Ms. Bassett earned her Juris Doctor, with high honors, from The George Washington University Law School, where she was a member of the Order of the Coif and served on the Moot Court and Alternative Dispute Resolution boards. She holds a Bachelor of Arts in Political Science and English, magna cum laude and with distinction in political science, from Duke University. Known for her steady judgment and collaborative approach, she is committed to building strong teams, mentoring emerging legal leaders, and helping organizations navigate complex issues with clarity and confidence.
OUR AWARDS
URAC-Accredited Pharmacy Benefit Manager
LucyRx is proud to be a URAC-Accredited PBM, meeting nationally recognized standards of quality, transparency, and accountability in pharmacy benefit management. This distinction reflects our ongoing commitment to delivering clinically sound, transparent, and cost-effective pharmacy solution.
David Blair
Chief Executive Officer
David Blair has over 25 years of experience investing in and operating companies in the pharmacy services and ancillary markets. In 2023, David Blair, along with other leading industry professionals, founded LucyRx in response to the pressing demand for value-added pharmaceutical services companies. Serving as the Chief Executive Officer of LucyRx, David’s team aims to offer vital solutions for health plans grappling with substantial rises in complex, high-cost specialty drugs.
From 1998 through 2012, Mr. Blair served as chairman and chief executive officer of Catalyst Health Solutions Inc., a Fortune 500 company that was acquired by SXC Health Solutions in 2012 for $4.8 billion.
On average, Catalyst doubled in size every two years, earning a position on Fortune’s 100 Fastest-Growing Companies list five times and recognition as a Fortune 500 company in 2012. Catalyst was also the recipient of numerous prestigious healthcare and financial industry awards including Fortune’s “World’s Most Admired Companies”; the Washington Post 200, URAC Award for Best Practices in Health Care; e-Healthcare Leadership Awards; Interactive Media Awards for its drug pricing tools and three Pharmacy Benefit Management Institute Rx Benefit Innovation Awards.
Mr. Blair’s management skills and accomplishments resulted in numerous awards and recognition including Forbes America’s 15 Most Powerful CEOs under 40 (years of age). In addition to his philanthropic activities, Mr. Blair has remained active in the healthcare industry since the sale of Catalyst. Mr. Blair has both started and invested in numerous healthcare companies, including Gateway Health Partners, among others in the healthcare and pharmacy services spaces. Mr. Blair holds a B.A. in finance from Clemson University.
Lankford Wade
President and Chief Financial Officer
Lankford Wade is a transformative leader with more than 20 years of experience driving financial excellence and operational growth in the healthcare sector. As President and Chief Financial Officer of LucyRx, he oversees financial strategy and operations, ensuring the company delivers innovative, cost-effective solutions to clients while maintaining the highest standards of operational efficiency.
Lankford’s career is defined by a commitment to delivering value for stakeholders. Before joining LucyRx, he served as CEO of UpStream, where he repositioned the company for improved financial performance while advancing patient care initiatives. As CFO of Summit Health, Lankford was instrumental in scaling the organization, integrating the Summit Medical Group and CityMD, navigating tremendous growth in the face of the COVID-19 pandemic, and leading the company through its $8.9 billion acquisition by VillageMD.
Beyond his operational achievements, Lankford brings extensive expertise in building scalable infrastructure and fostering growth. At U.S. Anesthesia Partners and Aetna, he spearheaded initiatives to enhance financial systems, optimize operations, and deliver measurable results for clients and stakeholders.
A summa cum laude graduate of Princeton University with a degree in Economics, Lankford’s extensive experience reflects a commitment to innovation, strategic leadership, and delivering impactful results.
Martin Payne
EVP, Chief Strategy Officer
Martin J. Payne, has more than 30 years of experience in executive and board positions in a mix of private and public, global enterprises. Mr.Payne’s current board positions are with SK Growth Opportunities (NASDAQ: SKGRU) and Astraius, a satellite launch company.
Mr. Payne has served in board leadership positions at MedX and Comprehensive Clinical Solutions, where he led strategic and operational transformation efforts, including the successful, over-subscribed, IPO launch of HCARU, raising over $330 million.
In addition to multiple entrepreneurial successes, Mr. Payne was formerly with Catalyst Health Solutions (formerly NASDAQ: CHSI), leading the highly value-accretive M&A transactions and integrations of HospiScript, IPS, Total Script, InPharmative, Future Scripts, Walgreens Health Initiatives, and RegenceRx; during which time Catalyst’s stock price rose fourfold. Prior to his tenure with Catalyst, Mr. Payne served in executive leadership roles at Coventry Health Care (formerly NYSE: CVH), Hanger Orthopedic Group (NYSE: HNGR), and United Health Group (NYSE: UNH).
Mr. Payne started his career in the Royal Navy as a helicopter pilot. Mr. Payne is a graduate of the University of Essex.
Alexander Motola
EVP, Chief Business Officer
Mr. Motola has over a decade of experience in finance, healthcare investing, and capital markets. He has completed 30+ M&A transactions representing over $10 billion in aggregate transaction value. His investment experience spans the capital structure (including majority and minority equity, senior and junior debt) and company stage (public, buyout, growth, and venture).
From 2021 to 2023, Mr. Motola served as a senior investment professional at a boutique special situations private equity fund focused on the healthcare and technology sectors, where he led transaction sourcing and execution, as well as operational value creation initiatives. Prior to that, he held investment and advisory roles at Baird, Twin Brook Capital Partners (a subsidiary strategy of Angelo, Gordon), and BMO Capital Markets. Mr. Motola earned his B.B.A. in Finance and Economics from the University of Iowa and his M.B.A. from UCLA Anderson School of Management.
Susan Thomas
Chief Commercial Officer
Susan P. Thomas is a seasoned business executive with over three decades of leadership experience in the healthcare sector, demonstrating a robust clinical background and a keen acumen for business growth and strategy. She holds an MBA from the University of Virginia’s Darden School of Business and a Bachelor of Science in Nursing from the same institution, providing her with a rare blend of healthcare expertise and business insight. Throughout her extensive career, Susan has held high-impact roles at major healthcare organizations including CatalystRx, OptumRx and Elixir, where she spearheaded significant initiatives leading to remarkable growth in client bases and revenue.
Currently serving as Chief Commercial Officer at LucyRx in Bethesda, MD, Susan is responsible for driving the development and execution of market strategies. Previously, as a senior leader at Optum Rx and more recently at Elixir, Susan managed large teams and multi-billion dollar budgets, consistently enhancing client satisfaction and retention through innovative solutions and strong team leadership. Her career is distinguished by her commitment to integrating advanced technology solutions, improving operational efficiencies, and fostering an environment of engagement and high performance within her teams.
Lori Hart
Chief Human Resources Officer
Lori Hart is an accomplished human resources leader with more than 20 years of experience driving talent strategy, organizational development, and workforce transformation across the healthcare industry. As Chief Human Resources Officer at LucyRx, she leads all aspects of talent strategy, culture, and people operations, ensuring the company attracts, develops, and retains top talent to support its rapid growth and mission to transform pharmacy benefits.
Before joining LucyRx, Lori served as Vice President of Human Resources at Compassus, where she led HR strategy for a workforce of nearly 6,000 employees across hospice, home health, and palliative care services. Prior to that, she was Vice President of Human Resources at Option Care Health, where she played a key role in workforce integration following the company’s merger with BioScrip, helping to scale the business to over $3 billion in revenue.
Lori brings deep expertise in talent development, leadership coaching, mergers and acquisitions, workforce planning, and employee engagement. She has also held HR leadership roles at UnitedHealth Group/OptumRx, Oregon Lottery, and IHS Markit, where she developed scalable HR infrastructures, implemented strategic workforce initiatives, and guided organizations through periods of growth and change.
A Gallup Strengths Performance Coach, Lori is passionate about creating purpose-driven workplaces where employees thrive. She has also served on multiple nonprofit boards, reflecting her commitment to community impact and leadership.
Anuj Agrawal
Chief Transformation Officer
Anuj Agrawal is a strategic technology leader with over 25 years of experience in healthcare and pharmacy benefits management (PBM). As Chief Transformation Officer at LucyRx, he is responsible for driving the company’s digital transformation and operational innovation, leading the migration from on-premise infrastructure to the cloud to enhance scalability, security, and regulatory compliance. Anuj’s leadership ensures that LucyRx’s technology ecosystem remains at the forefront of data security and AI-driven innovation, with a strong commitment to HIPAA and SOC 2 Type 2 alignment.
Before joining LucyRx, Anuj held senior leadership positions at Elixir and UnitedHealth Group (Optum), where he spearheaded technology modernization and transformation initiatives. At Elixir, he served as Head of Technology Services, leading the modernization of PBM platforms, rebate aggregation systems, and core systems integration. At Optum, Anuj oversaw UnitedHealthcare’s flagship portals, mobile platforms, and clinical systems supporting complex specialty care, while also leading major cloud migration initiatives and implementing AI-driven solutions to boost efficiency and cost savings.
Anuj holds a Master of Science in Computer Science from the University of Missouri-Kansas City and a Bachelor of Science in Mechanical Engineering from the National University of Singapore. His career reflects a commitment to leveraging technology for strategic growth and operational excellence, positioning LucyRx as a leader in healthcare innovation and data-driven solutions.